Morbidity and mortality due to infectious diseases have been dramatically reduced by improved vaccination, which is the most cost-effective public health measure to prevent spread of disease (Lambert et al., 2005). Most vaccines are given by intramuscular injection, even though the muscle is not a highly immunogenic organ (Hutin et al., 2003, Hohlfeld and Engel, 1994). The skin, in contrast, is a much more attractive site for vaccination from an immunologic perspective, because of its many resident dendritic cells and efficient drainage to lymph nodes (Debenedictis et al., 2001, Kupper and Fuhlbrigge, 2004).
We are excited by such strong immunogenicity results, which is the result of a novel approach to vaccination.
2018 Siegriest CA. et al., Phase I, double-blind, placebo-controlled, randomized safety and immunogenicity trial of reactivation of pertussis toxin immunity with an investigational epicutaneous patch in healthy adults
Link to study
The Benefits for Health Care
LESS VACCINATION NEEDED
Due enhanced immune response
NO COLD CHAIN
Dry formulation of the patch vaccination eliminates the need for a cold chain
No risk of contamination through sharp waste due to needleless delivery
Needleless delivery allows painless vaccination procedure
EASY & FAST SCALEABLE
Simple procedure facilitates a high throughput also with non medical staff
Lower average cost per vaccination compared with vial/cold chain/syringe costs
Higher reproducibility (compared to than micro needles or ID)
up to 7 times lower packaging volume compared to vials